Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fléchon A, Jain RK, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST. Loriot Y, et al. Among authors: jain rk. Clin Cancer Res. 2024 Aug 1;30(15):3179-3188. doi: 10.1158/1078-0432.CCR-23-3924. Clin Cancer Res. 2024. PMID: 39086310 Clinical Trial.
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. Li R, et al. Among authors: jain rk. Clin Cancer Res. 2023 Oct 2;29(19):3875-3881. doi: 10.1158/1078-0432.CCR-23-0354. Clin Cancer Res. 2023. PMID: 37505486 Clinical Trial.
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.
Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D'Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY. Sweis RF, et al. Among authors: jain rk. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1728. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576210
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mulé JJ, Conejo-Garcia JR. Li R, et al. Among authors: jain rk. Nat Med. 2024 Nov 9. doi: 10.1038/s41591-024-03324-9. Online ahead of print. Nat Med. 2024. PMID: 39521884
Site of breast cancer metastasis is independent of single nutrient levels.
Abbott KL, Subudhi S, Ferreira R, Gültekin Y, Steinbuch SC, Munim MB, Honeder SE, Kumar AS, Ramesh DL, Wu M, Hansen JA, Sivanand S, Riedmayr LM, Duquette M, Ali A, Henning N, Shevzov-Zebrun A, Gourgue F, Barbeau AM, Waite M, Kunchok T, Ferraro GB, Do BT, Spanoudaki V, Sánchez-Rivera FJ, Jin X, Church GM, Jain RK, Vander Heiden MG. Abbott KL, et al. Among authors: jain rk. bioRxiv [Preprint]. 2024 Oct 25:2024.10.24.616714. doi: 10.1101/2024.10.24.616714. bioRxiv. 2024. PMID: 39484531 Free PMC article. Preprint.
1,403 results